Bailard Inc. Takes $269,000 Position in SI-BONE, Inc. (NASDAQ:SIBN)

Bailard Inc. purchased a new position in shares of SI-BONE, Inc. (NASDAQ:SIBN) in the fourth quarter, HoldingsChannel.com reports. The firm purchased 12,800 shares of the company’s stock, valued at approximately $269,000.

A number of other large investors have also recently bought and sold shares of SIBN. Brown Advisory Inc. raised its holdings in shares of SI-BONE by 1.1% in the third quarter. Brown Advisory Inc. now owns 3,993,614 shares of the company’s stock valued at $84,824,000 after buying an additional 41,731 shares during the last quarter. Vanguard Group Inc. raised its stake in SI-BONE by 7.2% during the 3rd quarter. Vanguard Group Inc. now owns 2,308,516 shares of the company’s stock valued at $49,033,000 after acquiring an additional 155,121 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in SI-BONE by 2.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 678,360 shares of the company’s stock worth $14,408,000 after acquiring an additional 17,449 shares during the period. Wellington Management Group LLP grew its stake in shares of SI-BONE by 5.4% in the 3rd quarter. Wellington Management Group LLP now owns 605,839 shares of the company’s stock valued at $12,868,000 after purchasing an additional 31,051 shares during the last quarter. Finally, Impax Asset Management Group plc increased its holdings in shares of SI-BONE by 35.7% in the third quarter. Impax Asset Management Group plc now owns 475,343 shares of the company’s stock valued at $10,096,000 after purchasing an additional 125,000 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.

Insider Buying and Selling

In related news, Director Mika Nishimura sold 2,500 shares of SI-BONE stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total transaction of $40,550.00. Following the completion of the transaction, the director now directly owns 19,350 shares of the company’s stock, valued at $313,857. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other SI-BONE news, insider Anthony J. Recupero sold 3,330 shares of the company’s stock in a transaction dated Wednesday, March 13th. The shares were sold at an average price of $16.82, for a total value of $56,010.60. Following the sale, the insider now owns 255,760 shares of the company’s stock, valued at $4,301,883.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mika Nishimura sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The stock was sold at an average price of $16.22, for a total transaction of $40,550.00. Following the transaction, the director now directly owns 19,350 shares of the company’s stock, valued at $313,857. The disclosure for this sale can be found here. Insiders have sold a total of 11,562 shares of company stock worth $185,285 in the last quarter. Company insiders own 5.40% of the company’s stock.

SI-BONE Stock Performance

Shares of SIBN opened at $14.57 on Monday. The company has a current ratio of 9.01, a quick ratio of 8.15 and a debt-to-equity ratio of 0.21. SI-BONE, Inc. has a 52-week low of $14.12 and a 52-week high of $29.51. The company has a 50-day simple moving average of $16.60 and a 200-day simple moving average of $18.14.

SI-BONE (NASDAQ:SIBN) last issued its earnings results on Monday, February 26th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. The company had revenue of $38.86 million for the quarter, compared to analyst estimates of $38.60 million. On average, analysts predict that SI-BONE, Inc. will post -0.98 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages recently weighed in on SIBN. Needham & Company LLC reaffirmed a “buy” rating and set a $27.00 price target on shares of SI-BONE in a report on Wednesday, April 3rd. Truist Financial restated a “buy” rating and issued a $24.00 target price (down previously from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a research note on Tuesday, February 27th. Morgan Stanley raised their price objective on shares of SI-BONE from $25.00 to $26.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, Piper Sandler began coverage on SI-BONE in a research report on Thursday, March 28th. They set an “overweight” rating and a $25.00 target price on the stock. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat, SI-BONE presently has an average rating of “Buy” and a consensus price target of $26.67.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.